{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:25Z","timestamp":1785526825583,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cavernous sinus meningiomas represent a significant clinical challenge, given the high prevalence of neurological deficits and limited surgical options. Radiation therapy is often the preferred treatment. This study evaluates the effectiveness of fractionated stereotactic radiation therapy (fSRT) in achieving local control and symptomatic relief in patients with cavernous sinus meningiomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-institution retrospective analysis of patients with symptomatic presumed WHO grade 1 cavernous sinus meningiomas treated with fSRT (1.8\u20132\u00a0Gy per fraction). Clinical data were collected by chart review. Kaplan-Meier curves were generated to assess local control. Clinical responses were evaluated for symptom improvement, stability, or worsening at \u2264\u200936 months, 36\u201360 months, 60\u2013120 months, 120\u2013180 months, and &gt;\u2009180 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study identified 39 patients treated with fSRT who met inclusion criteria. Median age was 60 years (range 21\u201379), with a median Karnofsky Performance Score (KPS) of 90. Median follow-up time was 122.2 months. Median tumor volume was 10.0\u00a0cc (range 3.6\u201318.3\u00a0cc). Local control rates at 1, 3, 5, and 10 years were 100%, 94.6%, 91.7%, and 88.1%, respectively. Of 39 patients, 26 (66.7%) demonstrated clinical improvement following fSRT, 9 (23.1%) remained clinically unchanged, and 4 (10.3%) experienced worsening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrated fSRT achieves effective local control for cavernous sinus meningioma. Notably, 2\/3 of patients achieved neurological symptom improvement after radiation. Larger, prospective studies are warranted to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05688-z","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:44:43Z","timestamp":1782783883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes"],"prefix":"10.1007","volume":"178","author":[{"given":"Ryan","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shray","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"Supplement4","key":"5688_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C et al (2023) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020. Neurooncology 25(Supplement4):iv1\u2013iv99. https:\/\/doi.org\/10.1093\/neuonc\/noad149","journal-title":"Neurooncology"},{"issue":"3","key":"5688_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","volume":"99","author":"J Wiemels","year":"2010","unstructured":"Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99(3):307\u2013314. https:\/\/doi.org\/10.1007\/s11060-010-0386-3","journal-title":"J Neurooncol"},{"issue":"14","key":"5688_CR3","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1002\/cncr.29379","volume":"121","author":"TA Dolecek","year":"2015","unstructured":"Dolecek TA, Dressler EVM, Thakkar JP, Liu M, Al-Qaisi A, Villano JL (2015) Epidemiology of meningiomas post-Public Law 107\u2013206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer 121(14):2400\u20132410. https:\/\/doi.org\/10.1002\/cncr.29379","journal-title":"Cancer"},{"issue":"1","key":"5688_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-006-9146-9","volume":"80","author":"K Korhonen","year":"2006","unstructured":"Korhonen K, Salminen T, Raitanen J, Anssi Auvinen, Isola J, Hannu H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1\u20137. https:\/\/doi.org\/10.1007\/s11060-006-9146-9","journal-title":"J Neurooncol"},{"key":"5688_CR5","doi-asserted-by":"publisher","unstructured":"Wang J, Landry A, Raleigh D et al (2024) Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients. Neurooncology 26(10). https:\/\/doi.org\/10.1093\/neuonc\/noae082","DOI":"10.1093\/neuonc\/noae082"},{"key":"5688_CR6","doi-asserted-by":"publisher","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology 23(8). https:\/\/doi.org\/10.1093\/neuonc\/noab106","DOI":"10.1093\/neuonc\/noab106"},{"issue":"1","key":"5688_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1227\/01.neu.0000068730.76856.58","volume":"53","author":"M Nakamura","year":"2003","unstructured":"Nakamura M, Roser F, Michel J, Jacobs C, Samii M (2003) The Natural History of Incidental Meningiomas. Neurosurgery 53(1):62\u201371. https:\/\/doi.org\/10.1227\/01.neu.0000068730.76856.58","journal-title":"Neurosurgery"},{"issue":"4","key":"5688_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11940-010-0081-x","volume":"12","author":"J Raizer","year":"2010","unstructured":"Raizer J, Meningiomas (2010) Curr Treat options Neurol 12(4):360\u2013368. https:\/\/doi.org\/10.1007\/s11940-010-0081-x","journal-title":"Curr Treat options Neurol"},{"key":"5688_CR9","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.wneu.2017.12.012","volume":"111","author":"A Wu","year":"2018","unstructured":"Wu A, Garcia MA, Magill ST et al (2018) Presenting Symptoms and Prognostic Factors for Symptomatic Outcomes Following Resection of Meningioma. World Neurosurg 111:e149\u2013e159. https:\/\/doi.org\/10.1016\/j.wneu.2017.12.012","journal-title":"World Neurosurg"},{"issue":"2","key":"5688_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s10143-021-01652-9","volume":"45","author":"SAM Hosainey","year":"2021","unstructured":"Hosainey SAM, Bouget D, Reinertsen I et al (2021) Are there predilection sites for intracranial meningioma? A population-based atlas. Neurosurg Rev 45(2):1543\u20131552. https:\/\/doi.org\/10.1007\/s10143-021-01652-9","journal-title":"Neurosurg Rev"},{"key":"5688_CR11","doi-asserted-by":"publisher","unstructured":"Stafford SL, Perry A, Suman VJ et al (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic Patients, 1978 Through 1988. Mayo Clinic Proceedings 73(10):936\u2013942. https:\/\/doi.org\/10.4065\/73.10.936","DOI":"10.4065\/73.10.936"},{"issue":"2","key":"5688_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3171\/2015.3.jns142494","volume":"125","author":"A Nanda","year":"2016","unstructured":"Nanda A, Thakur JD, Sonig A, Missios S (2016) Microsurgical resectability, outcomes, and tumor control in meningiomas occupying the cavernous sinus. J Neurosurg 125(2):378\u2013392. https:\/\/doi.org\/10.3171\/2015.3.jns142494","journal-title":"J Neurosurg"},{"issue":"16","key":"5688_CR13","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.3390\/cancers14164047","volume":"14","author":"A Santacroce","year":"2022","unstructured":"Santacroce A, Constantin Tuleasca, Li\u0161\u010d\u00e1k R et al (2022) Stereotactic radiosurgery for benign cavernous sinus meningiomas: a multicentre study and review of the literature. Cancers 14(16):4047\u20134047. https:\/\/doi.org\/10.3390\/cancers14164047","journal-title":"Cancers"},{"issue":"3","key":"5688_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3171\/2013.5.jns13206","volume":"119","author":"BE Pollock","year":"2013","unstructured":"Pollock BE, Stafford SL, Link MJ, Garces YI, Foote RL (2013) Single-fraction radiosurgery of benign cavernous sinus meningiomas. J Neurosurg 119(3):675\u2013682. https:\/\/doi.org\/10.3171\/2013.5.jns13206","journal-title":"J Neurosurg"},{"issue":"6","key":"5688_CR15","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2019.3.focus1970","volume":"46","author":"N Fatima","year":"2019","unstructured":"Fatima N, Meola A, Pollom EL, Soltys SG, Chang SD (2019) Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis. NeuroSurg Focus 46(6):E2. https:\/\/doi.org\/10.3171\/2019.3.focus1970","journal-title":"NeuroSurg Focus"},{"key":"5688_CR16","unstructured":"National Comprehensive Cancer Network Central Nervous System Cancers (Version 2.2026). Retrieved from https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1%26id=1425"},{"issue":"1","key":"5688_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.surneu.2005.06.027","volume":"65","author":"M Brell","year":"2006","unstructured":"Brell M, Vill\u00e0 S, Teixidor P, Lucas A, Ferr\u00e1n E, Mar\u00edn S, Acebes JJ (2006) Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. Surg Neurol 65(1):28\u201334. https:\/\/doi.org\/10.1016\/j.surneu.2005.06.027","journal-title":"Surg Neurol"},{"issue":"4","key":"5688_CR18","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2008.09.012","volume":"74","author":"CF Litr\u00e9","year":"2009","unstructured":"Litr\u00e9 CF, Colin P, Noudel R, Peruzzi P, Bazin A, Sherpereel B, Bernard MH, Rousseaux P (2009) Fractionated stereotactic radiotherapy treatment of cavernous sinus meningiomas: a study of 100 cases. Int J Radiat Oncol Biol Phys 74(4):1012\u20131017. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.09.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5688_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ijrobp.2009.08.006","volume":"78","author":"P Metellus","year":"2010","unstructured":"Metellus P, Batra S, Karkar S, Kapoor S, Weiss S, Kleinberg L, Rigamonti D (2010) Fractionated conformal radiotherapy in the management of cavernous sinus meningiomas: long-term functional outcome and tumor control at a single institution. Int J Radiat Oncol Biol Phys 78(3):836\u2013843. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5688_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1748-717X-9-27","volume":"9","author":"SF Correa","year":"2014","unstructured":"Correa SF, Marta GN, Teixeira MJ (2014) Neurosymptomatic carvenous sinus meningioma: a 15-years experience with fractionated stereotactic radiotherapy and radiosurgery. Radiation Oncol (London England) 9:27. https:\/\/doi.org\/10.1186\/1748-717X-9-27","journal-title":"Radiation Oncol (London England)"},{"issue":"11","key":"5688_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00066-006-1548-2","volume":"182","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J (2006) Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas: long-term experience and review of the literature. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft \u2026 et al] 182(11):635\u2013640. https:\/\/doi.org\/10.1007\/s00066-006-1548-2","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft \u2026 et al]"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05688-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:12Z","timestamp":1785521052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05688-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5688"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05688-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board at Sidney Kimmel Cancer Center, with a waiver of informed consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WS has received consulting fees from Varian, Brainlab, and Novocure. JJE has received consulting fees from Mizuho. No competing interests are declared by RS, SJ, NH, LAH, RLW, CJF, DH, or GSA.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}